Kubra Ekinci is a visiting PhD student in the Rahman Lab at King’s College London. She is a final-year doctoral candidate at Ankara University, Biotechnology Institute, where her research focuses on designing STAT3 inhibitors for cancer therapy. Her work combines structure-based drug design methods, including virtual screening, docking, and pharmacophore modelling, with biological validation.
She has prior experience as a Regulatory Affairs Specialist at the Turkish Medicines and Medical Devices Agency, where she oversaw biotechnology-based products such as anticancer drugs and vaccines. She has expertise in both computational and molecular biology methods, enabling her to bridge in silico and experimental approaches in drug discovery.